TY - JOUR T1 - Amitriptyline and topiramate are no better than placebo for childhood migraine JF - Archives of disease in childhood - Education & practice edition JO - Arch Dis Child Educ Pract Ed DO - 10.1136/archdischild-2017-312734 SP - edpract-2017-312734 AU - Rebecca A Dalrymple AU - Ian Wacogne Y1 - 2017/02/28 UR - http://ep.bmj.com/content/early/2017/02/28/archdischild-2017-312734.abstract N2 - Setting: 31 sites in the USA.Patients: Children and adolescents aged 8–17 years with a diagnosis of migraine plus Pediatric Migraine Disability Assessment Score (PedMIDAS) indicating mild to severe disability and four or more headaches over the initial 28 day baseline period.Intervention: 1 mg/kg/day amitriptyline versus 2 mg/kg/day topiramate versus placebo. There was a 28-day period initially before medication started to monitor baseline migraine frequency, the active medication was started and dose slowly increased for 8 weeks with 16-week maintenance period, to complete 24 weeks in total.Outcomes: Primary outcome was relative reduction of 50% or more in number of headache days between the initial 28-day baseline period and the last 28-day period of the trial.Secondary outcomes included headache disability (change in PedMIDAS score), reduction in the … ER -